Literature DB >> 16434024

Intermedin1-53 activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas.

Jing-Hui Yang1, Chun-Shui Pan, Yue-Xia Jia, Jing Zhang, Jing Zhao, Yong-Zheng Pang, Jun Yang, Chao-Shu Tang, Yong-Fen Qi.   

Abstract

Intermedin (IMD), a novel member of the calcitonin/calcitonin gene-related peptide (CGRP) family, has similar or more potent vasodilatory and hypotensive actions than adrenomedullin (ADM) and CGRP. The present study was designed to observe the effects of synthetic rat IMD1-53 on L-arginine (L-Arg) cellular transport, nitric oxide synthase (NOS) activity, and nitric oxide (NO) production in the isolated rat aortic ring to illustrate its direct effect on the L-Arg/NOS/NO pathway in vasculature. IMD1-53 significantly increased NO production and cNOS activity in rat aortas and was more potent than equivalent ADM. But the peptides of both IMD and ADM had no effect on inducible NOS expression and activity. Otherwise, IMD1-53 induced a concentration-dependent increase in [3H]L-Arg transport and its effect was more potent than that of an equivalent concentration of ADM. Semiquantitative RT-PCR revealed that IMD1-53 significantly increased cationic amino acid transport (CAT)-1 and CAT-2B mRNA expression, and its effect was similar to that of ADM. All these results suggest that IMD1-53 might regulate vessel function homeostasis via upregulating the L-Arg/NOS/NO pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434024     DOI: 10.1016/j.bbrc.2006.01.010

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases.

Authors:  Song-Yang Zhang; Ming-Jiang Xu; Xian Wang
Journal:  Br J Pharmacol       Date:  2017-05-16       Impact factor: 8.739

Review 2.  The pharmacology of adrenomedullin 2/intermedin.

Authors:  Yanguo Hong; Debbie L Hay; Remi Quirion; David R Poyner
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress.

Authors:  Makoto Hagiwara; Grant Bledsoe; Zhi-Rong Yang; Robert S Smith; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

Review 4.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

5.  Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats.

Authors:  L Jolly; J E March; P A Kemp; T Bennett; S M Gardiner
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

6.  Effects of continuous intermedin infusion on blood pressure and hemodynamic function in spontaneously hypertensive rats.

Authors:  Ying Yuan; Xi Wang; Qiang Zeng; Hong-Mei Wu; Yong-Fen Qi; Chao-Shu Tang
Journal:  J Geriatr Cardiol       Date:  2012-03       Impact factor: 3.327

7.  Plasma Intermedin Level Indicates Severity and Treatment Efficacy of Septic Shock in Sprague-Dawley (SD) Rats.

Authors:  Su-Xian Yang; Yun-Xiu Chen; Jing Xu; Zhao-Hui Yang
Journal:  Med Sci Monit       Date:  2016-12-21

8.  Intermedin1‑53 enhances angiogenesis and attenuates adverse remodeling following myocardial infarction by activating AMP‑activated protein kinase.

Authors:  Kankai Chen; Meiling Yan; Yongguang Li; Zhifeng Dong; Dong Huang; Jingbo Li; Meng Wei
Journal:  Mol Med Rep       Date:  2017-02-10       Impact factor: 2.952

9.  Intermedin 1-53 Inhibits Myocardial Fibrosis in Rats by Down-Regulating Transforming Growth Factor-β.

Authors:  Jian Fang; Jiangwei Luan; Gaohong Zhu; Chang Qi; Zhiyong Yang; Sheng Zhao; Bin Li; Xinzhong Zhang; Naipeng Guo; Xiaodong Li; Dandan Wang
Journal:  Med Sci Monit       Date:  2017-01-09

10.  Intermedin1-53 attenuates aging-associated vascular calcification in rats by upregulating sirtuin 1.

Authors:  Yao Chen; Lin-Shuang Zhang; Jin-Ling Ren; Ya-Rong Zhang; Ning Wu; Mo-Zhi Jia; Yan-Rong Yu; Zhong-Ping Ning; Chao-Shu Tang; Yong-Fen Qi
Journal:  Aging (Albany NY)       Date:  2020-03-31       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.